English
Back
Download
Log in to access Online Inquiry
Back to the Top

UPDATES

$Immutep (IMMP.US)$ Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.

INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.

It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemotherapy as a potential first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer.

The biotechnology firm said that the first overall survival results, issued on Nov. 14, 2024, from the trial showed mature data in patients with a minimum follow-up of 22 months achieved a median overall survival of 32.9 months and a 24-month overall survival rate of 81%.

The company's shares rose past 1% in recent Monday trade.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1644 Views
Comment
Sign in to post a comment
    198
    Followers
    38
    Following
    841
    Visitors
    Follow
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.